We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PSH market cap is 44.08M. The company's latest EPS is CAD -0.0980 and P/E is -2.04.
| Year End October 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 551k | 0 | 0 | 0 | 0 |
| Operating Income | -5.03M | -6.62M | -24.12M | -39.66M | -28.53M |
| Net Income | -5.32M | -6.97M | -24.42M | -39M | -32.19M |
| Year End October 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 5.73M | 29.82M | 52.49M | 22.11M | 7.53M |
| Total Liabilities | 1.58M | 1.75M | 4.88M | 9.59M | 20.48M |
| Total Equity | 4.14M | 28.07M | 47.61M | 12.52M | -12.96M |
| Year End October 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -3.94M | -6.85M | -14.42M | -30.34M | -18.9M |
| Investing | 995k | -228k | -46.34M | 34.78M | 11.12M |
| Financing | 5.1M | 31M | 36.66M | 503k | 5.07M |
| Market Cap | 44.08M |
| Price to Earnings Ratio | -2.04 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 10.93 |
| Price to Book Ratio | -5.07 |
| Dividend Yield | - |
| Shares Outstanding | 328.48M |
| Average Volume (1 week) | 72.24k |
| Average Volume (1 Month) | 62.37k |
| 52 Week Change | -68.42% |
| 52 Week High | 0.48 |
| 52 Week Low | 0.1131 |
| Spread (Intraday) | 0 (3.7%) |
| Company Name | Sernova Biotherapeutics Inc |
| Address |
suite 1500 - 1055 west georgia street vancouver, british columbia V6E 2N7 |
| Website | https://www.sernova.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
